Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Accounts Payables (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Accounts Payables data on record, last reported at $5.1 million in Q3 2025.

  • For Q3 2025, Accounts Payables rose 543.51% year-over-year to $5.1 million; the TTM value through Sep 2025 reached $5.1 million, up 543.51%, while the annual FY2024 figure was $6.4 million, 7.73% up from the prior year.
  • Accounts Payables reached $5.1 million in Q3 2025 per SNTI's latest filing, up from $1.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $12.6 million in Q4 2022 and bottomed at $28.0 in Q1 2021.
  • Average Accounts Payables over 5 years is $3.8 million, with a median of $2.7 million recorded in 2023.
  • Peak YoY movement for Accounts Payables: surged 2079900.0% in 2022, then crashed 80.39% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $5.2 million in 2021, then soared by 142.45% to $12.6 million in 2022, then crashed by 52.87% to $5.9 million in 2023, then grew by 7.73% to $6.4 million in 2024, then dropped by 20.08% to $5.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $5.1 million in Q3 2025, $1.0 million in Q2 2025, and $1.6 million in Q1 2025.